Developments in high-yield system expressed vaccines and immuno-therapy

Recent Patents on Biotechnology

Volumn 4, Issue 3, 2010, Pages 189-197

  Geels, Marissa ^a   Ye, Kaiming ^a  

^a University of Arkansas   (United States)

Author keywords

Antigen delivery systems; Cell surface protein display; Immunotherapy; Influenza vaccine; Vaccine production; Viral vectors

Indexed keywords

CELL MEMBRANES; COST EFFECTIVENESS; VIRUSES;

ANTIGEN DELIVERY SYSTEM; CELL SURFACE PROTEIN DISPLAY; CELL SURFACE PROTEINS; CELLULAR RESPONSE; HIGHER YIELD; IMMUNOTHERAPY; INFLUENZA VACCINES; PRODUCTION TECHNIQUES; VACCINE PRODUCTION; VIRAL VECTORS;

VACCINES;

ALUMINUM POTASSIUM SULFATE; CHIMERIVAX; DNA VACCINE; HAEMOPHILUS INFLUENZAE VACCINE; INFLUENZA VACCINE; LIVE VACCINE; RECOMBINANT HEPATITIS B VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE; VIRUS VECTOR; WART VIRUS VACCINE;

ADAPTIVE IMMUNITY; ARTICLE; CELL SURFACE; CLINICAL TRIAL; DRUG DESIGN; DRUG FORMULATION; EPITOPE MAPPING; GENE EXPRESSION SYSTEM; GENETIC REASSORTMENT; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOTHERAPY; INNATE IMMUNITY; MASS IMMUNIZATION; NONHUMAN; PASSIVE IMMUNIZATION; PATENT; PHAGE DISPLAY; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN EXPRESSION; RECOMBINANT DNA TECHNOLOGY; VACCINE PRODUCTION; VIRUS VIRULENCE;

EID: 78649999330     PISSN: 18722083     EISSN: None     Source Type: Journal    
DOI: 10.2174/187220810793611518     Document Type: Article

References (33)

1. Amorij JP, Huckriede A, Wilschut J, Frijlink HW, Hinrichs WLJ. Development of stable influenza vaccine powder formulations: challenges and possibilities. Pharm Res 2008; 25: 1256-1273.
2. World Health Organization. Global pandemic influenza action plan to increase vaccine supply: progress report 2008. Initiative for Vaccine Research. Printed April 2009. www.who.int/vaccines-documents/.
3. Zhu K, Chi Z, Li J, Zhang F, Li M, Yasoda HN, et al. The surface display of haemolysin from Vibrio harveyi on yeast cells and their potential applications as live vaccine in marine fish. Vaccine. 2006; 24: 6046-6052.
4. Jadhao SJ, Achenbach J, Swayne DE, Donis R, Cox N, Matsuoka Y. Development of Eurasian H7N7/PR8 high growth reassortant virus for clinical evaluation as an inactivated pandemic influenza vaccine. Vaccine. 2008; 26: 1745-1750.
5. Alexander J, Bilsel P, Guercio MF, Stewart S, Marinkovic-Petrovic A, Southwood S, et al. Universal influenza DNA vaccine encoding conserved CD4+ T cell epitopes protects against lethal viral challenge in HLA-DR transgenic mice. Vaccine 2010; 28: 664-672.
6. Rodriquez LL, Grubman MJ. Foot and mouth disease virus vac-cines. Vaccine 2009: 27: D90-D94.
7. Shivachandra SB, Li Q, Peachman KK, Matyas GR, Leppla SH, Alving CR, et al. Multicomponent antrax toxin display and delivery using bacteriophage T4. Vaccine 2007; 25: 1225-1235.
8. Forsgren, A., Riesbeck, K. Novel surface exposed Haemophilus Influenzae protein (protein E;pE). US20090246219 (2009).
9. Sung, M.H., Poo, H.R., Lee, J.S., Jung, C.M., Hong, S.P., Kim, C.J., Park, S., Pyo, H.M. Vector for anti-HPV vaccine and transformed microorganism by the vector. US20090117151A1 (2009).
10. Lee, S.Y., Lee, S.H., Park, S.J. Method for cell surface display of target proteins using fadl of E.coli. US20070105150A1 (2007).
11. Guy B, Guirakhoo F, Barban V, Higgs S, Monath TP, Lang J. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile, and Japanese encephalitis viruses. Vaccine 2010; 28: 632-649.
12. Hubbell JA, Thomas SN, Swartz MA. Materials engineering for immunomodulation. Nature 2009; 462: 449-60.
13. Deblaere, R.Y., Desomer, J., Dhaese, P. Expression of surface layer proteins: US20020048816 (2002).
14. Pail JC, Sutherland JN, Maynard JA. Progress towards recombinant anti-infective antibodies. Recent Pat Antiinfect Drug Discov 2009; 4: 1-17.
15. Law M, Hangartner L. Antibodies against viruses: passive and active immunization. Curr Opin Immunol 2008; 20: 486-492.
16. Doring G, Pier GB. Vaccines and immunotherapy against Pseudo-monas aeruginosa. Vaccine 2008; 26: 1011-1024.
17. Goldstein G, Chicca JJ. A universal anti-HIV-1Tat epitope vaccine that is fully synthetic and self-adjuvanting. Vaccine 2009; 28: 1008-1014.
18. Hodgson, J.E., Burnham, M.K.R. Cell surface protein compounds. US6299880 (2001).
19. Brun A, Albina E, Barret T, Chapman DA, Czub M, Dixon LK, et al. Antigen delivery systems for veterinary vaccine development viral vector based delivery systems. Vaccine 2008; 26: 6508-6528.
20. Polakova I, Pokorna D, Duskova M, Smahel M. DNA vaccine against human papillomavirus type 16:modifications of the E6 on-cogene. Vaccine 2009; 28: 1506-1513.
21. Meinke, A., Nagy, E., Hanner, M., Horky, M., Kallenda, S., Prus-tomersky, S. New nucleic acid molecule encoding a hyper immune serum reactive antigen, useful for the manufacture of a vaccine against Streptococcuc agalactiae infection. US2004000556060 (2006).
22. Potgieter T, Cukan M, Drummond JE. Production of monoclonal antibodies by glycoengineered Pichia Pastoris. J Biotechnol 2009; 139: 318-325.
23. Giritch A, Marillonnet S, Engler C, Eldik Gerben van, Botterman J, Klimyuk V, et al. Rapid high-yield expression of full-size IgGanti-bodies in plants coinfected with noncompeting viral vectors. Proc Natl Acad Sci USA 2006; 103: 14701-14706.
24. Lee SL, Choi JH, Xu Z. Microbial cell-surface display. Trends Biotechnol 2003; 21: 45-42.
25. Lee JS, Shin KS, Pan JG, Kim CJ. Surface-displayed viral antigens on Salmonella carrier vaccine. Nat Biotechnol 2000; 18: 645-648.
26. Majander K, Korhonen TK, Westerlund-Wikstrom B. Simultaneous display of multiple foreign peptides in the FLID capping and Flic filament proteins of the Escherichia coli flagellum. Appl Environ Microbiol 2005; 71: 4263-4268.
27. Kniskern, P.J., Arpi, H. Hepatitis B virus surface proteins with reduced host carbohydrate content. EP0000303883 (1992).
28. Kniskern, P.J., Hagopian, A. HBsAg escape mutant vaccine. US000692922 (1992).
29. Solomon B. Generation of anti-beta-amyloid antibodies via phage display technology towards Alzheimer's disease vaccination. Vaccine 2005; 23: 2327-2330.
30. Lin YH, Lee LH, Shih WL, Hu YC, Liu HJ. Baculovirus surface display of cC and gB proteins of avian reovirus and immunogenic-ity of the displayed proteins in a mouse model. Vaccine 2008; 26: 6361-6367.
31. Van Houten NE, Henry KA, Smith GP, Scott JK. Engineering filamentous phage careeiers, to improve focusing of antibody responses against peptides. Vaccine 2010; 28: 2174-21785
32. Joo HM, He Y, Sundararajan A, Huan L, Sangster MY. Quantitative analysis of influenza virus-specific B cell memory generated by different routes of inactivated virus vaccination. Vaccine 2010; 28: 2186-2194
33. Tritto E, Mosca F, Gregorio ED. Mechanism of action of licensed vaccine adjuvants. Vaccine 2009; 27: 3331-3334.